- Survival results from AGENDA Phase 3 trial of Genasense ® in advanced melanoma on track for expected followup completion in Q1 2011
- Tesetaxel Phase 2a-2b studies now open in 4 indications: gastric, breast and bladder cancer, and melanoma
- Scientific Advice for Phase 3 study of tesetaxel in gastric cancer received from European Medicines Agency (EMA). Regulatory discussions ongoing with other agencies.
- Tesetaxel clinical data in breast and gastric cancer to be presented at the San Antonio Breast Cancer Symposium, the AACR/NIH/EORTC “Targets” Meeting, and the Chemotherapy Foundation meeting
- Pharmacokinetic data from Ganite ® clinical study in patients with serious infections presented at North American Cystic Fibrosis meeting.
Genta Incorporated Reports Third Quarter 2010 Corporate Highlights And Financial Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.